» Sign in / Register

FLT3 Ligand

Fms-like Tyrosine Kinase 3 Ligand

murine, recombinant, E. coli

Cat. No. Amount Price (EUR) Buy / Note
PR-421 10 μg 253,00 Add to Basket/Quote Add to Notepad

For in vitro use only!

Shipping: shipped at ambient temperature

Storage Conditions: store at -20 °C
avoid freeze/thaw cycles

Shelf Life: 12 months

Molecular Weight: 16.4 kDa

Accession number: P49772

Accession number: P49772

Purity: > 95 % (SDS-PAGE, RP-HPLC)

Form: lyophilised

Solubility: It is recommended to reconstitute the lyophilised FLT3 in sterile bidest H2O not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).

Activity: The activity is determined by the ability to generate CD11c+ splenic dendritic cells in vivo in C57B1/6-12 week female mice. To obtain the desired affect, mice were treated with approximately 25 μg of FLT-3 Ligand once daily for 9 consecutive days via intraperitoneal injection.

Recombinant murine FLT3 Ligand produced in E. coli is a non-glycosylated, polypeptide chain containing 144 amino acids and having a molecular mass of 16.4 kDa. FLT3 ligand is a receptor for the fl cytokine has a tyrosine-protein kinase activity & a growth factor that regulates proliferation of early hematopoietic cells. Flt3-Ligand synergizes with other CSFs and interleukins to induce growth and differentiation. Recombinant FLT3 Ligand is purified by proprietary chromatographic techniques.

Amino Acid Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Thr-Gln-Asp-Cys-Ser.

Selected References:
Ciavarra et al. (2004) Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. J. Immunother. 27:13.
Ciavarra et al. (2003) Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol. Immunother. 52:535.
Somers et al. (2003) Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy. Int. J. Cancer 107:773.
Agrawal et al. (2001) Flt3 ligand: a novel cytokine prevents allergic asthma in a mouse model. Int. Immunopharmacol. 1:2081.
Li et al. (2001) Neutralization of IL-12 reverses rejection of mouse liver allografts from Flt3-ligand-treated donors and is associated with suppression of both cellular and humoral responses. Transplant. Proc. 33:525.